[{"data":1,"prerenderedAt":62},["ShallowReactive",2],{"q-nurse-112-1-medical-surgical-039":3},{"subject":4,"subjectSlug":5,"subjectFullName":4,"question":6,"related":32,"lastmod":61},"內外科護理學","medical-surgical",{"id":7,"webId":8,"year":9,"session":10,"subject":4,"number":11,"stem":12,"options":13,"answer":18,"answerNote":19,"images":20,"explanation":21,"explanationDeep":22,"topics":23,"freq":10},"nurse-112-1-內外科護理學-039","nurse-112-1-medical-surgical-039",112,1,39,"有關癌症分期系統類型之敘述，下列何者錯誤？",{"A":14,"B":15,"C":16,"D":17},"治療前的臨床分期，可以 cTNM 表示","手術後切除病理組織做的分期，可以 sTNM 表示","復發或再次治療，可以 rTNM 表示","治療後分期，可用 ycTNM 表示","B",null,[],"本題考點在於TNM癌症分期系統的前綴符號。依分期命名規則,手術後依切除病理組織所做的分期以病理分期pTNM表示(p代表pathologic),而非sTNM,故錯誤敘述為B。A治療前的臨床分期以cTNM(clinical)表示,正確;C復發或再次治療以rTNM(recurrent)表示,正確;D新輔助治療後的臨床分期可用ycTNM(y代表治療後)表示,正確,故皆非答案。","TNM前綴口訣:c=clinical臨床(治療前理學與影像)、p=pathologic病理(術後標本)、y=治療後(neoadjuvant後,如ypTNM、ycTNM)、r=recurrent復發再分期、a=autopsy屍檢。T=腫瘤大小、N=淋巴結、M=遠端轉移。分期是治療決策與預後判斷的核心語言,前綴誤植會改變臨床解讀。",[24,26,28,30],{"term":25,"count":10},"TNM分期系統",{"term":27,"count":10},"病理分期pTNM",{"term":29,"count":10},"臨床分期cTNM",{"term":31,"count":10},"治療後與復發前綴",[33,37,42,47,52,57],{"webId":34,"stem":35,"number":36,"year":9,"session":10},"nurse-112-1-medical-surgical-040","有關癌症病人血小板減少症之處置，下列何者正確？",40,{"webId":38,"stem":39,"number":40,"year":9,"session":41},"nurse-112-2-medical-surgical-056","下列何者是誘發病人發生急性呼吸窘迫症候群（ARDS）最常見的危險因子？",56,2,{"webId":43,"stem":44,"number":45,"year":46,"session":10},"nurse-113-1-medical-surgical-020","有關下肢深部靜脈栓塞服用Warfarin病人之護理指導，下列何者正確？",20,113,{"webId":48,"stem":49,"number":50,"year":51,"session":41},"nurse-114-2-medical-surgical-018","有關預防靜脈血栓形成之措施，下列何者不適當？",18,114,{"webId":53,"stem":54,"number":55,"year":56,"session":10},"nurse-106-1-medical-surgical-022","有關急性中耳炎感染途徑之敘述，下列何者錯誤？",22,106,{"webId":58,"stem":59,"number":40,"year":60,"session":10},"nurse-107-1-medical-surgical-056","有關慢性阻塞性肺部疾病病人使用 Aminophylline 治療時之敘述，下列何者正確？①主要作用為支氣管擴張 ②副作用為心律不整和高血壓 ③靜脈注射速度不可超過 20～25 mg\u002Fmin ④血清治療濃度應維持在 20～40 μg\u002FmL 之間",107,"2026-09-04",1788510742034]